TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3511182

Group type: EXPERIMENTAL
Intervention: Urabe Am 9‐Schwarz vaccine
Number of subjects: 400

Group type: COMPARATOR
Intervention: Jeryl Lynn‐Moraten vaccine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 400
Study: 29483078

Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT) using Flexicult™ SSIUrinary Kit
Number of subjects: 329

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Point-of-care testing (POCT) and Standard care
Number of subjects: 329
Study: 27470259

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group (SEG) therapy
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Body-mind-spirit (BMS) intervention
Number of subjects: 157

Group type: COMPARATOR
Intervention: Social support control group
Number of subjects: 157
Study: 25240070

Group type: EXPERIMENTAL
Intervention: Adapted interpersonal psychotherapy
Number of subjects: 113

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 113
Study: 22211699

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 6415
Study: 21054990

Group type: EXPERIMENTAL
Intervention: Tecnis ZM900 multifocal intraocular lens (TMF)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Restor SA60D3 multifocal intraocular lens (Restor)
Number of subjects: 73
Study: 18207461

Group type: EXPERIMENTAL
Intervention: Level II ultrasonography
Number of subjects: 150

Group type: COMPARATOR
Intervention: Level III ultrasonography
Number of subjects: 150
Study: 18515465

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15188939

Group type: EXPERIMENTAL
Intervention: Hypertensive patients receiving contemporary medical therapy
Number of subjects: 3326

Group type: COMPARATOR
Intervention: Non-hypertensive patients receiving contemporary medical therapy
Number of subjects: 3326
Study: 12363115

Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg/day
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Haloperidol 10 mg/day
Number of subjects: 414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg/day and Haloperidol 10 mg/day
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 414
Study: 9389264

Group type: COMPARATOR
Intervention: Nitrous oxide at 0 vol.%
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 20 vol.%
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 40 vol.%
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 60 vol.%
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 45 vol.%
Number of subjects: 64
Study: 7947240

Group type: EXPERIMENTAL
Intervention: rHuEPO (200 units/kg intravenous bolus daily) for 28 days or until Hct of 35% reached
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: rHuEPO treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 10
Study: 3332575

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS, 30 or 60 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, 25 or 50 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11739337

Group type: EXPERIMENTAL
Intervention: Pharmaceutical industry support
Number of subjects: 314

Group type: COMPARATOR
Intervention: Non-industry support
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Overall study outcomes
Number of subjects: 314
Study: 31718757

Group type: EXPERIMENTAL
Intervention: Higher deprivation score (multidimensional poverty index)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Higher deprivation score (quintiles)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Lower self-reported income (quintiles)
Number of subjects: 323
Study: 30075959

Group type: EXPERIMENTAL
Intervention: Mini-sternotomy (MS)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Full median sternotomy (FS)
Number of subjects: 222
Study: 26305413

Group type: EXPERIMENTAL
Intervention: Nordic pole walking (NPW) training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional treadmill training (TT)
Number of subjects: 70
Study: 24697872

Group type: EXPERIMENTAL
Intervention: Oral terbinafine for 2 weeks and topical terbinafine and 10% urea ointment for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical terbinafine and 10% urea ointment for 12 weeks
Number of subjects: 0
Study: 22051697

Group type: EXPERIMENTAL
Intervention: Variants in the CRTAM gene associated with low vitamin D levels
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Functional studies on cell lines
Number of subjects: 987
Study: 20142572

Group type: EXPERIMENTAL
Intervention: Automated telephone outreach with speech recognition (ATO‐SR) - a single interactive outreach call
Number of subjects: 20938

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20938
Study: 18271228

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (needling method at Baihui (GV 20), Shenting (GV 24), Shenmen (HT 7))
Number of subjects: 46

Group type: COMPARATOR
Intervention: Estazolam (oral administration)
Number of subjects: 46
Study: 16218175

Group type: EXPERIMENTAL
Intervention: Autologous fat transfer (AFT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Polylactic acid (PLA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Polyacrylamide hydrogel (PAAG)
Number of subjects: 59
Study: 12165551

Group type: EXPERIMENTAL
Intervention: IL-10
Number of subjects: 329
Study: 10102158

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (HDIVIG) therapy (1 g kg(‐1), over 4 h) with phototherapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional phototherapy alone
Number of subjects: 116
Study: 8896153

Group type: EXPERIMENTAL
Intervention: MRI examination of supraspinatus tendons
Number of subjects: 4

Group type: COMPARATOR
Intervention: MRI examination of healthy volunteers
Number of subjects: 4
Study: 2197716

Group type: EXPERIMENTAL
Intervention: inpatient family intervention (IFI)
Number of subjects: 92

Group type: COMPARATOR
Intervention: multimodal hospital treatment without IFI
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: multimodal hospital treatment with IFI
Number of subjects: 92
Study: 21504

Group type: EXPERIMENTAL
Intervention: HC 20‐511 4 mg daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HC 20‐511 2 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cyproheptadine (Periactin) 8 mg daily
Number of subjects: 50
Study: 31296834

Group type: EXPERIMENTAL
Intervention: CR and IMT (Inspiratory Muscle Training)
Number of subjects: 90

Group type: COMPARATOR
Intervention: CR only
Number of subjects: 90

Group type: COMPARATOR
Intervention: IMT only
Number of subjects: 90
Study: 29048182

Group type: EXPERIMENTAL
Intervention: Smoking abstinence on Day 1 (D1)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Smoking abstinence on Day 3 (D3)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Craving during the follicular phase
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Craving during the luteal phase
Number of subjects: 125
Study: 25504143

Group type: EXPERIMENTAL
Intervention: Stress management support (SMS) tool with instruction to link stressful situations with healthy snack alternatives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stress management support (SMS) tool without linking instruction (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stress management support (SMS) tool with linking instruction (experimental)
Number of subjects: 0
Study: 24734908

Group type: COMPARATOR
Intervention: Setipiprant 2000 mg single dose
Number of subjects: 16

Group type: COMPARATOR
Intervention: Setipiprant 500 mg b.i.d. for 5.5 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Setipiprant 1000 mg b.i.d. for 5.5 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Setipiprant (single and multiple doses)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Setipiprant with food
Number of subjects: 16

Group type: COMPARATOR
Intervention: Urinary excretion of unchanged setipiprant
Number of subjects: 16
Study: 22946083

Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention for mothers of children newly diagnosed with cancer
Number of subjects: 52

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 52
Study: 19685416

Group type: EXPERIMENTAL
Intervention: Strength training (10 weeks of progressive strength training)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 74
Study: 16824797

Group type: EXPERIMENTAL
Intervention: Specialized basketball training (SP)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mixed basketball plus conditioning training (MX)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 15001199

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg plus Indapamide 0.625 mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Atenolol 50 mg
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Perindopril/Indapamide
Number of subjects: 201
Study: 15187802

Group type: EXPERIMENTAL
Intervention: Pemoline (75 to 112.5 mg, titrated over 4 weeks to a single morning dose for 12 weeks)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Pemoline
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: COMPARATOR
Intervention: Pemoline and Placebo
Number of subjects: 69
Study: 11328223

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone followed by gemeprost 1 mg vaginally
Number of subjects: 896

Group type: COMPARATOR
Intervention: 600 mg mifepristone followed by gemeprost 1 mg vaginally
Number of subjects: 896

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 896

Group type: COMPARATOR
Intervention: 600 mg mifepristone
Number of subjects: 896
Study: 9219072

Group type: EXPERIMENTAL
Intervention: Various interventions identified in RCTs
Number of subjects: 56

Group type: COMPARATOR
Intervention: Electronic searches for trials
Number of subjects: 56
Study: 7955441

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) replacement therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 3298936

Group type: EXPERIMENTAL
Intervention: GIP (2 pmol/kg/min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isotonic NaCl
Number of subjects: 18
Study: 30286455

Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenytoin and Megestrol
Number of subjects: 0
Study: 27848149

Group type: EXPERIMENTAL
Intervention: High managerial experience (HME)
Number of subjects: 68
Study: 25818264

Group type: EXPERIMENTAL
Intervention: Intralesional injection of collagenase Clostridium histolyticum (CCH) 0.58 mg
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 1044
Study: 24340995

Group type: EXPERIMENTAL
Intervention: HyperHAES solution used during prolonged veno-venous haemofiltration
Number of subjects: 0
Study: 21516302

Group type: EXPERIMENTAL
Intervention: Gefitinib (12 weeks)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo (12 weeks)
Number of subjects: 115
Study: 18292446

Group type: EXPERIMENTAL
Intervention: Epidural neostigmine (1 microg/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 45
Study: 16825047

Group type: EXPERIMENTAL
Intervention: Mineralized collagen bone graft substitute combined with bone marrow aspirate
Number of subjects: 25

Group type: COMPARATOR
Intervention: Iliac crest autograft
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 25
Study: 12955428

Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide administered 1 hour before stenting and every 8 hours for 3 weeks
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo administered 1 hour before stenting and every 8 hours for 3 weeks
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 10757623

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 8631519

Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Specific measurable goals
Number of subjects: 44

Group type: COMPARATOR
Intervention: Broad, generalised aims
Number of subjects: 44
Study: 1581773

Group type: EXPERIMENTAL
Intervention: Thoracospinal hyperostosis
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Shoulder hyperostosis
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Elbow hyperostosis
Number of subjects: 85
Study: 4082903

Group type: EXPERIMENTAL
Intervention: Increased ratio of carbidopa to levodopa (1:4)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard ratio of carbidopa to levodopa (1:10)
Number of subjects: 11
Study: 29973117

Group type: EXPERIMENTAL
Intervention: Education with fluorescent gel
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Interactive education
Number of subjects: 96

Group type: COMPARATOR
Intervention: Normal education (control group)
Number of subjects: 96
Study: 28323043

Group type: EXPERIMENTAL
Intervention: High dose vitamin D3 (20,000 IU twice a week)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Standard dose (placebo)
Number of subjects: 297
Study: 27411750

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) use at baseline
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) use at 52 weeks
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: CAM use at baseline
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: CAM use
Number of subjects: 640
Study: 24929430

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 563

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study: 23107894

Group type: EXPERIMENTAL
Intervention: Carvedilol (C, 20 then 40 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Valsartan (V, 160 then 320 mg/day)
Number of subjects: 30
Study: 19295224

Group type: EXPERIMENTAL
Intervention: Real laser needle acupuncture (Laserneedle Computer-System), 8 sessions of 20 min each over 3 menstrual cycles.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo laser needle acupuncture (no laser activity), 8 sessions of 20 min each over 3 menstrual cycles.
Number of subjects: 48
Study: 17264716

Group type: EXPERIMENTAL
Intervention: Tubes telescoped into catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tubes warmed in saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tubes at room temperature (control)
Number of subjects: 0
Study: 15084215

Group type: EXPERIMENTAL
Intervention: 12‐lead simultaneous ECG (12‐SIM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: lead II ECG (LEAD II)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3‐LEAD ECG
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: computer‐based, proprietary algorithm, 12SL trade mark ECG Analysis software (AUT)
Number of subjects: 10
Study: 11792769

Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate-buffered peritoneal dialysis (TBL; 25 mM/15 mM bicarbonate/lactate, pH 7.3)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lactate-buffered peritoneal dialysis (LPD; 40 mM lactate, pH 5.2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of TBL and LPD at 6 months
Number of subjects: 10
Study: 10023500

Group type: EXPERIMENTAL
Intervention: SSRI plus inositol
Number of subjects: 27

Group type: COMPARATOR
Intervention: SSRI plus placebo
Number of subjects: 27
Study: 7594424

Group type: EXPERIMENTAL
Intervention: Hypertensives
Number of subjects: 94

Group type: COMPARATOR
Intervention: Normotensives
Number of subjects: 94
Study: 1724914

Group type: EXPERIMENTAL
Intervention: T3 50 micrograms/d
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: (T4 50 micrograms/d + T3 12.5 micrograms) x 2
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: T4 150 micrograms + iodide 150 micrograms/d
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: T4 75 micrograms + T3 18.75 micrograms/d
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: T4 200 micrograms/d
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: T3 37.5 micrograms/d
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Iodide 300 micrograms/d
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: T4 150 micrograms/d
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Iodide 150 micrograms/d
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 7398983

Group type: EXPERIMENTAL
Intervention: Local application of hair lotions with 17 alpha-estradiol (0.025%)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (hair lotions without 17 alpha-estradiol)
Number of subjects: 51
Study: 6833654

Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Diltiazem 270 mg/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day
Number of subjects: 21
Study: 29523624

Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 1420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1420
Study: 26463318

Group type: EXPERIMENTAL
Intervention: ODM-201 (600 mg dose in capsules and tablets)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ODM-201 (600 mg twice daily in capsules)
Number of subjects: 30
Study: 24890573

Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification (ABM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no ABM)
Number of subjects: 0
Study: 23135530

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine 0.05% (group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.5% carboxymethylcellulose (control; group B)
Number of subjects: 70
Study: 20813689

Group type: EXPERIMENTAL
Intervention: Oxymatrine (150 mg daily, intravenously)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gluthion (1.2 g daily, intravenously)
Number of subjects: 80
Study: 18445355

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for weight loss (5% to 10% of initial body weight)
Number of subjects: 0
Study: 15144909

Group type: EXPERIMENTAL
Intervention: Collaborative case management intervention
Number of subjects: 246

Group type: COMPARATOR
Intervention: Usual care with educational materials
Number of subjects: 246
Study: 11527895

Group type: EXPERIMENTAL
Intervention: One embryo transfer
Number of subjects: 144

Group type: COMPARATOR
Intervention: Two embryo transfer
Number of subjects: 144
Study: 9523481

Group type: EXPERIMENTAL
Intervention: Cord blood and 3 days of age samples from healthy infants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal children (7 to 17 years)
Number of subjects: 0
Study: 8201768

Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup at 3 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup at 5 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup at 10 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup at 15 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup (overall clinical efficacy)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup at daily doses of 12 - < 18 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup at daily doses of 18 - < 27 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup at daily doses of 27 - < 33 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: SY5555 dry syrup (bacteriological eradication)
Number of subjects: 64
Study: 2883952

Group type: EXPERIMENTAL
Intervention: Nasal spray of LHRH, 0.4 mg thrice daily during 28 consecutive days
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Nasal spray of LHRH, 0.4 mg twice daily on alternate days for 1 month
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Nasal spray of LHRH, 0.4 mg twice daily on alternate days for 3 months
Number of subjects: 93
Study: 29731444

Group type: EXPERIMENTAL
Intervention: CSP 200mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CSP 400mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CSP 400mg + Metformin 600mg (DT1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CSP 400mg (DT2)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Metformin 600mg (PC)
Number of subjects: 6
Study: 26434382

Group type: EXPERIMENTAL
Intervention: Lidocaine gel group (3 mL 2% lidocaine gel applied to the cervix and intrauterine infusion of 5 mL normal saline)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion group (3 mL gel lubricant applied to the cervix and intrauterine infusion of 5 mL 2% lidocaine)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo group (3 mL gel lubricant applied to the cervix and intrauterine infusion of 5 mL normal saline)
Number of subjects: 120
Study: 25034216

Group type: EXPERIMENTAL
Intervention: Simultaneous initiation of insulin pump therapy (Medtronic Veo©) and continuous glucose monitoring (CGM) (Enlite©)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard pump therapy with delayed CGM introduction
Number of subjects: 144
Study: 22253393

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 20178056

Group type: EXPERIMENTAL
Intervention: Intensified multimodal work-related programme following a cognitive behavioural approach
Number of subjects: 236

Group type: COMPARATOR
Intervention: Common orthopaedic rehabilitation
Number of subjects: 236
Study: 17118998

Group type: EXPERIMENTAL
Intervention: 0.1 mg TAK-677 BID (n = 21)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 0.5 mg TAK-677 BID (n = 22)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo BID (n = 22)
Number of subjects: 65